X. Ling

发表

Identification and validation of an eight-lncRNA signature that predicts prognosis in patients with esophageal squamous cell carcinoma

Jian-qun Ma, Jinfeng Zhang, X. Ling, 2022, Cellular & Molecular Biology Letters.

Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma.

Yanjing Li, Junqing Gan, Mingxia Jiang, 2021, Chemico-biological interactions.

LncRNA HAR1A Suppresses the Development of Non-Small Cell Lung Cancer by Inactivating the STAT3 Pathway

Jinhong Zhu, X. Ling, Kui Cao, 2022, Cancers.

TMEM139 prevents NSCLC metastasis by inhibiting lysosomal degradation of E‐cadherin

Yingyin Zhang, Qijia Xuan, X. Ling, 2022, Cancer science.

Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma

Jinhong Zhu, X. Ling, Kui Cao, 2022, Respiratory Research.

ATM – Chk 2 – p 53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca 1 deficiency

Noboru, Motoyama, X. Coumoul, 2013 .

Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase Ⅱ, single-arm, exploratory research.

Wei Zheng, D. Zheng, Xiaoyuan Wang, 2021 .

Improvement of ACK1-targeted therapy efficacy in lung adenocarcinoma using chloroquine or bafilomycin A1

Jinhong Zhu, Meng Zhao, Yuwen Bai, 2023, Molecular Medicine.

The construction and analysis of the aberrant lncRNA-miRNA-mRNA network in non-small cell lung cancer.

Jinhong Zhu, Cheng Fang, H. Yin, 2019, Journal of thoracic disease.

Integrated analysis of immune infiltration in esophageal carcinoma as prognostic biomarkers

Xue Leng, Jinhong Zhu, H. Yin, 2021, Annals of translational medicine.

Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment

Xin Eric Wang, D. Zheng, Jinhong Zhu, 2022, Cancer Immunology, Immunotherapy.

65P Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research

W. Zheng, X. Wang, Y. Xin, 2021, Annals of Oncology.

Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2.

Peng Huang, Yanjing Li, Y. Bai, 2019, European journal of pharmacology.

Development of immune gene pair-based signature predictive of prognosis and immunotherapy in esophageal cancer

Jinhong Zhu, Mingdong Liu, X. Ling, 2021, Annals of translational medicine.

Identification and validation of an eight-lncRNA signature that predicts prognosis in patients with esophageal squamous cell carcinoma

Jinfeng Zhang, X. Ling, Chengyuan Fang, 2022, Cellular & molecular biology letters.

Analysis of multiple programmed cell death-related prognostic genes and functional validations of necroptosis-associated genes in oesophageal squamous cell carcinoma

Jinfeng Zhang, X. Ling, Kui Cao, 2023, EBioMedicine.

METTL3-mediated deficiency of lncRNA HAR1A drives non-small cell lung cancer growth and metastasis by promoting ANXA2 stabilization

Jinfeng Zhang, X. Ling, Kui Cao, 2024, Cell death discovery.

Single-cell RNA sequencing reveals distinct transcriptomic profiles and evolutionary patterns in lung cancer brain metastasis

X. Ling, Yingnan Yang, Xiaoyuan Wang, 2024, Heliyon.

Nucleoporin 93, a new substrate of the E3 ubiquitin protein ligase HECTD1, promotes esophageal squamous cell carcinoma progression.

Jinfeng Zhang, X. Ling, Chengyuan Fang, 2023, Human cell.

406 Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: a phase II, single-arm, exploratory research

Wei Zheng, D. Zheng, Haoyuan Jiang, 2021, Journal for ImmunoTherapy of Cancer.

Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study)

Haoyuan Jiang, Jinfeng Zhang, X. Ling, 2023, International journal of surgery.